These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23075669)

  • 1. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
    Sinsakul M; Sika M; Koury M; Shapiro W; Greene T; Dwyer J; Smith M; Korbet S; Lewis J;
    Nephron Clin Pract; 2012; 121(1-2):c25-9. PubMed ID: 23075669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
    Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP;
    Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
    Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
    J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
.
    Hain DJ; Marinaro M; Koeper DW; Rosenthal MA; Chillemi S; Huffman JM; Gerbeling T; Pritsiolas JM; Loram LC; Pergola PE
    Clin Nephrol; 2017 Jul; 88(1):12-18. PubMed ID: 28561732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial.
    Lee CT; Lee CC; Wu MJ; Chiu YW; Leu JG; Wu MS; Peng YS; Wu MS; Tarng DC
    PLoS One; 2022; 17(3):e0264727. PubMed ID: 35239732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
    Zhuang B; Gan L; Liu B; Yuan W; Shi M; Peng A; Wang L; Chen X; Liu T; Zhang S; Wang S; Gao Q; Wang B; Zheng H; Liu C; Luo Y; Ye H; Lin H; Li Y; He Q; Zheng F; Luo P; Long G; Lu W; Li K; Yang J; Liu YC; Zhang Z; Li X; Zhang W; Zuo L
    Nephrol Dial Transplant; 2024 Sep; 39(10):1649-1661. PubMed ID: 38453435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate.
    Navarrete JE; Ajiboye O; Lea JI
    Perit Dial Int; 2024 Mar; 44(2):133-140. PubMed ID: 37691436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
    Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
    J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study.
    Wang Y; Chen X; Zhu H; Guo Z; Yang Y; Luo P; He Y; Xu Y; Ji D; Gao X; Sun X; Xing C; Wang Y; Wang X; Zhao S; Guan Y; Lin H; Zhong A; Shui H; Shao F; Lv L; Yan Y; Sun X; Zhang L
    Am J Nephrol; 2023; 54(11-12):479-488. PubMed ID: 37812931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis.
    Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M
    Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of SBR759, a new iron-based phosphate binder.
    Block GA; Brillhart SL; Persky MS; Amer A; Slade AJ
    Kidney Int; 2010 May; 77(10):897-903. PubMed ID: 20375984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
    Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
    Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.